Human Immunodeficiency Virus Type 1 Envelope Glycoprotein and CD3 T-cell Receptor Complex (HIV-1 Env/CD3)

The HIV-1 Envelope Glycoprotein (Env) and CD3 T-cell Receptor Complex represent a dual-target strategy used in the development of bispecific antibodies and T-cell engagers to treat HIV-1 infection. HIV-1 Env, consisting of gp120 and gp41 subunits, is expressed on the surface of both actively replicating and reactivated latently infected cells, serving as a specific marker for the viral reservoir. CD3 is a co-receptor on T cells essential for signal transduction and T-cell activation. By simultaneously binding to Env on infected cells and CD3 on cytotoxic T lymphocytes, therapeutic agents can bridge the two cells, bypassing the requirement for traditional MHC-I antigen presentation. This interaction triggers the formation of an artificial immunological synapse, leading to T-cell degranulation and the release of perforins and granzymes that selectively eliminate the HIV-infected cells. This approach is a cornerstone of 'shock and kill' therapeutic strategies aimed at reducing or eradicating the latent HIV reservoir in patients receiving antiretroviral therapy.

Other names

HIV-1 Env x CD3gp120/CD3gp41/CD3HIV-1 Envelope/CD3 bispecific targetHIV-1 Env-CD3

T-cell redirection and activation leading to the lysis of HIV-infected cells expressing the envelope glycoprotein.